Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada

PharmacoEconomics

Volumn 24, Issue 8, 2006, Pages 815-830

  Kohli, Michele ^a   Attard, Cheryl ^a   Lam, Annette ^a   Huse, Daniel ^a   Cook, John ^b   Bourgault, Chantal ^c,d   Alemao, Evo ^b   Yin, Donald ^b   Marentette, Michael ^c  

^a i3 Global   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; COLESTYRAMINE; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HYPERLIPIDEMIA; LONG TERM CARE; MALE; MEDICAL ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES;

EID: 33747154424     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624080-00007     Document Type: Article

References (85)

1. Heart and Stroke Foundation of Canada. The growing burden of heart disease and stroke in Canada. Ottawa (ON): Heart and Stroke Foundation of Canada, 2003
2. Health Canada. Economic burden of illness in Canada, 1998. Ottawa (ON): Health Canada, 2002
3. Start with your heart [online]. Available from URL: http:// startwithyourheart.com/Default.htm?.page=http%3A//startw ithyourheart.com/ glossary.htm [Accessed 2004 May 1]
4. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946-52
5. Bang LM, Goa KL. Pravastatin: a review of its use in elderly patients. Drugs Aging 2003; 20: 1061-82
6. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
8. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
9. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
10. Genest J, Frohlich J, Fodor G, et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003; 169: 921-4
11. Kastelein J, Van Dam M. A new role for combination therapy in lipid management. Br J Cardiol 2001; 8 (11): 639-53
12. Fodor JG, Frohlich JJ, Genest Jr JJ, et al. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000; 162: 1441-7
13. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000; 86 (12A): 35L-40L
14. Chong PH, Bachenheimer BS. Current, new and future treatments in dyslipidaemia and atherosclerosis. Drugs 2000; 60 (1): 55-93
15. Turley SD. State of the art in cholesterol management: targeting multiple pathways. Am J Manag Care 2002; 8 (2 Suppl.): 29S-32S
16. Repchinshky C, Welbanks L, Bisson R, editors. CPS - compendium of pharmaceuticals and specialties. Ottawa (ON): Canadian Pharmaceutical Association, 2002
17. IMS Health Canada. Canadian Compuscript Audit, TRx moving annual total, Kirkland (QC). 2003 Dec
18. Gangé C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 2469-75
19. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-34
20. Bureau of Pharmaceutical Assessment. PROTOCOL P00692: a phase III double-blind efficacy and safety study of ezetimibe (SCH 58235) 10mg in addition to atorvastatin compared to placebo in subjects with primary hypercholesterolemia. 2003. 10-18-0001 (Data on file)
21. Ballantyne C, Houri J, Notarbartolo A, et al., for the Ezetimibe Study Group. Effect of ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107 (19): 2409-15
22. Melani L, Mills R, Hassman D, et al., for the Ezetimibe Study Group. Ezetimibe co-administered with pravastatin in 538 patients with primary hypercholesterolemia [abstract]. J Am Coll Cardiol 2002; 39: 139B
23. Lipka L, Kerzner B, Corbelli J, et al. Results of ezetimibe coadministered with lovastatin in 548 patients with primary hypercholesterolemia [abstract]. J Am Coll Cardiol 2003; 39: 430B
24. Knopp RH, Dujovne CA, Le Beaut A, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolemia: a pooled analysis from two controlled phase III clinical studies. Ezetimbe Study Group. Int J Clin Pract 2003 Jun; 57 (5): 363-8
25. Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002 Nov 15; 90 (10): 1084-91
26. Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 2004 Jul; 58 (7): 653-8
27. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005 May; 80 (5): 587-95
28. Cook JR, Yin D, Alemao E, et al. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics 2004; 22 Suppl. 3: 37-48
29. Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal. Application to Germany, Spain and Norway. Pharmacoeconomics 2004; 22 Suppl. 3: 49-61
30. Glick H, Heyse JF, Thompson D, et al. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care 1992; 8 (4): 719-34
31. Weinstein MC, Coxson PG, Williams LW, et al. Forecasting coronary heart disease incidence, mortality, and cost: the coronary heart disease policy model. Am J Public Health 1987; 77: 1417-26
32. Oster G, Epstein AM. Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol. Am J Public Health 1986; 76 (6): 647-56
33. Oster G, Epstein AM. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA 1987; 258 (17): 2381-7
34. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265 (9): 1145-51
35. Hamilton VH, Racicot FE, Zowall H, et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA 1995; 273 (13): 1032-8
36. Huse DM, Russell MW, Miller JD, et al. Cost-effectiveness of statins. Am J Cardiol 1998; 82 (11): 1357-63
37. Russell MW, Huse DM, Miller JD, et al. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 2001; 8 (1): 9-16
38. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from The Framingham Study. Am Heart J 2000; 139: 272-81
39. Kenemans P. Climacteric and postmenopause: definitions, terms and concept [online]. 2002 Oct 17. Available from URL: http: //www.womanlab.com/english/ professionals/menopausa lIssues1.htm [Accessed 2003 Mar 13]
40. Anderson K, Odell P, Wilson P, et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-8
41. Elveback LR, Connolly DC, Kurland LT. Coronary heart disease in residents of Rochester, Minnesota: II. Mortality, incidence, and survivorship, 1950-1975. Mayo Clin Proc 1981; 56 (11): 665-72
42. Eisenberg MS, Hallstrom A, Bergner L. Long-term survival after out-of-hospital cardiac arrest. N Engl J Med 1982; 306 (22): 1340-3
43. Gillum RF, Folsom A, Luepker RV, et al. Sudden death and acute myocardial infarction in a metropolitan area, 1970-1980. The Minnesota Heart Survey. N Engl J Med 1983; 309 (22): 1353-8
44. Goldman L, Cook F, Hashimotso B, et al. Evidence that hospital care for acute myocardial infarction has not contributed to the decline in coronary mortality between 1973-1974 and 1978-1979. Circulation 1982; 65 (5): 936-42
45. McGovern PG, Jacobs Jr DR, Shahar E, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation 2001; 104 (1): 19-24
46. Statistics Canada. Annual demographic statistics 2000 (catalogue 91-213). Ottawa (ON): Minister of Industry, 2001
47. The North American Menopause Society. Menopause Core Curriculum Study Guide [introduction]. 2002: 9-14
48. Connelly PW, MacLean DR, Horlick L, et al. Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ 1992; 146: 1977-87
49. Stachenko SJ, Reeder BA, Lindsay E, et al. Smoking prevalence and associated risk factors in Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ 1992; 146: 1989-96
50. Joffres MR, Hamet P, Rabkin SW, et al. Prevalence, control and awareness of high blood pressure among Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ 1992; 146: 1997-2005
51. Reeder BA, Liu L, Horlick L. Sociodemographic variation in the prevalence of cardiovascular disease. Can J Cardiol 1996; 12 (3): 271-7
52. Hux JE, Tang M. Patterns of prevalence and incidence of diabetes. Diabetes in Ontario practice atlas. Toronto (ON): Institute for Clinical Evaluative Sciences, 2002
53. Grover SA, Paquet S, Levinton C, et al. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med 1998; 158: 655-62
54. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148 (3): 447-55
55. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001; 4 (5): 348-61
56. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. JAMA 1997; 277: 535-42
57. Heart and Stroke Foundation of Canada. The changing face of heart disease and stroke in Canada. Ottawa (ON): Heart and Stroke Foundation of Canada, 1999: 1-107
58. 53. Metabolism-Atherogenesis Branch, National Heart, Lung, and Blood Institute, et al. The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
59. Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994; 120: 537-43
60. Bureau of Pharmaceutical Assessment. PROTOCOL P00693: a phase III double-blind efficacy and safety study of SCH 58235 (10mg) in addition to atorvastatin in subjects with coronary heart disease or multiple cardiovascular risk factors and with primary hypercholesterolemia not controlled by a starting dose (10mg) of atorvastatin 2003. 1-31-0002. (Data on file)
61. Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 1993; 153: 1321-9
62. Bureau of Pharmaceutical Assessment. PROTOCOLS P02173 & P02246: a multicenter, double-blind, randomized, placebo-controlled study to evaluate the lipid altering efficacy, safety, and tolerability of SCH 58235 when added to ongoing therapy with an HMG-CoA reductase inhibitor (statin) in patients with primary hypercholesterolemia, known coronary heart disease, or multiple cardiovascular risk factors [base study]. 2003. 11-9-0001. (Data on file)
63. Ontario Ministry of Health. Ontario drug benefit formulary: comparative drug index. 37th ed. Toronto (ON): Ontario Ministry of Health, 2001
64. Ontario Ministry of Health. Ontario schedule of benefits for physician services under the Health Insurance Act. Toronto (ON): Ontario Ministry of Health, 2001
65. Ontario Ministry of Health. Ontario schedule of benefits for laboratory services. Toronto (ON): Ontario Ministry of Health, 1999
66. Grover SA, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001; 24: 45-50
67. O'Brien JA, Caro I, Getsios D, et al. Diabetes in Canada: direct medical costs of major macrovascular complications. Value Health 2001; 4: 258-65
68. Statistics Canada. The consumer price index. Ottawa (ON): Statistics Canada, 2003
69. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83: 356-62
70. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102
71. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa (ON): CCOHTA Publications, 1997
72. Grover SA, Ho V, Lavoie F, et al. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? 2003; 163 (3): 333-9
73. Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567-72
74. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116: 408-16
75. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553-64
76. Perreault S, Hamilton VH, Lavoie F, et al. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther 1997; 10: 787-94
77. Riviere M, Wang S, Leclerc C, et al. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ 1997; 156: 991-7
78. Perreault S, Hamilton VH, Lavoie F, et al. Treating hyperlipidemia for the primary prevention of coronary disease: are higher dosages of lovastatin cost-effective? Arch Intern Med 1998; 158: 375-81
79. Perreault S, Levinton C, Le Lorier J. Efficacy and cost of HMGCoA reductase inhibitors in the treatment of patients with primary hyperlipidemia. Can J Clin Pharmacol 2000; 7: 144-54
80. Ganz DA, Kuntz KM, Jacobson GA, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme: a reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000; 132: 780-7
81. Jonsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17: 1001-7
82. Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998; 137 Suppl.: S111-6
83. Pickin DM, McCabe CJ, Ramsay LE, et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999; 82 (3): 325-32
84. Troche CJ, Tacke J, Hinzpeter B, et al. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur Heart J 1998; 19 Suppl. C: C59-65
85. Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001; 141: 727-34